Technical Analysis for OKUR - OnKure Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 16.29 | -6.91% | -1.21 |
OKUR closed down 6.91 percent on Friday, November 1, 2024, on 1.67 times normal volume. It was able to find support at its 50 day moving average. It was able to bounce off of its 200 day moving average, an important long-term support line.
Earnings due: Nov 11
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Flat | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Lizard Bullish | Bullish Day Trade Setup | -6.91% | |
| Pocket Pivot | Bullish Swing Setup | -6.91% | |
| Doji - Bullish? | Reversal | -6.91% | |
| Lower Bollinger Band Touch | Weakness | -6.91% | |
| NR7 | Range Contraction | -6.86% |
| Alert | Time |
|---|---|
| 1.5x Volume Pace | about 18 hours ago |
| Down 10% | about 19 hours ago |
| Fell Below 200 DMA | about 19 hours ago |
| Fell Below 50 DMA | about 19 hours ago |
| Down 1 ATR | about 20 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
OnKure is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, OnKure is building a robust pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic PI3Kα and has multiple programs designed to enable best-in-class targeting of this key oncogene.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Personalized Medicine Drug Design
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Personalized Medicine Drug Design
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 81.5 |
| 52 Week Low | 9.801 |
| Average Volume | 40,747 |
| 200-Day Moving Average | 16.24 |
| 50-Day Moving Average | 16.20 |
| 20-Day Moving Average | 18.02 |
| 10-Day Moving Average | 17.65 |
| Average True Range | 1.19 |
| RSI (14) | 32.89 |
| ADX | 29.64 |
| +DI | 8.51 |
| -DI | 26.47 |
| Chandelier Exit (Long, 3 ATRs) | 15.83 |
| Chandelier Exit (Short, 3 ATRs) | 19.21 |
| Upper Bollinger Bands | 19.45 |
| Lower Bollinger Band | 16.59 |
| Percent B (%b) | -0.11 |
| BandWidth | 15.87 |
| MACD Line | 0.24 |
| MACD Signal Line | 0.53 |
| MACD Histogram | -0.2927 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.65 | ||||
| Resistance 3 (R3) | 18.69 | 17.95 | 18.25 | ||
| Resistance 2 (R2) | 17.95 | 17.35 | 17.93 | 18.12 | |
| Resistance 1 (R1) | 17.12 | 16.98 | 16.75 | 17.08 | 17.99 |
| Pivot Point | 16.38 | 16.38 | 16.20 | 16.36 | 16.38 |
| Support 1 (S1) | 15.55 | 15.78 | 15.18 | 15.51 | 14.59 |
| Support 2 (S2) | 14.81 | 15.41 | 14.79 | 14.46 | |
| Support 3 (S3) | 13.98 | 14.81 | 14.33 | ||
| Support 4 (S4) | 13.94 |
